A 12/24-weeks, open, multi-centre, phase IV study on safety and efficacy of 2mg exenatide once weekly (Bydureon) in T2DM patients.

Trial Identifier: D5551L00018
Sponsor: AstraZeneca
NCTID:: NCT02533453
Start Date: January 2016
Primary Completion Date: December 2016
Study Completion Date: December 2016
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English translation
Korean translation

Trial Locations

Country Location
South Korea Busan, South Korea, 49241
South Korea Daegu, South Korea, 700-712
South Korea Daejeon, South Korea, 35015
South Korea Gwangju, South Korea, 61469
South Korea Incheon, South Korea, 405-760
South Korea Seongnam-si, South Korea, 13620
South Korea Seoul, South Korea, 06351
South Korea Seoul, South Korea, 03722
South Korea Seoul, South Korea, 06591
South Korea Seoul, South Korea, 03080
South Korea Seoul, South Korea, 05505
South Korea Seoul, South Korea, 08308
South Korea Seoul, South Korea, 130-872
South Korea Suwon-si, South Korea, 16499
South Korea Wonju-si, South Korea, 26426